TALDO1 and breast cancer: Further analysis on the subgroup of patients who were treated with endocrine therapy alone revealed that TALDO1 remains a predictive marker of high risk to recurrence, distant metastasis and risk of breast cancer death (P < 0.05), (Supplementary Table 3).